Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Discovery

• Publication date

  2015-05-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-15-0285PMID 25971938
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MET-Mutated NSCLC with Major Response to Crizotinib.

  2015cited by this paper
• Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

  2015cited by this paper
• MET Mutation Associated with Responsiveness to Crizotinib.

  2015cited by this paper
• Comprehensive molecular profiling of lung adenocarcinoma

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.

  2014cited by this paper
• Transcriptome Meta-Analysis of Lung Cancer Reveals Recurrent Aberrations in NRG1 and Hippo Pathway Genes

  2014cited by this paper
• Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

  2014cited by this paper
• LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT

  2014cited by this paper
• Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody

  2014cited by this paper
• Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.

  2014cited by this paper
• Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

  2013cited by this paper
• Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

  2013cited by this paper
• Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas

  2013cited by this paper
• Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.

  2012cited by this paper
• The transcriptional landscape and mutational profile of lung adenocarcinoma

  2012cited by this paper
• Chipping away at the lung cancer genome

  2012cited by this paper
• The genetic basis for cancer treatment decisions.

  2012cited by this paper
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

  2012cited by this paper
• MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

  2011cited by this paper
• Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

  2011cited by this paper
• Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

  2011cited by this paper
• Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

  2011cited by this paper
• A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

  2011cited by this paper
• Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.

  2010cited by this paper
• LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

  2009cited by this paper
• Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

  2009cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• The Met tyrosine kinase receptor in development and cancer

  2008cited by this paper
• Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer

  2008cited by this paper
• An alternatively spliced form of Met receptor is tumorigenic

  2006cited by this paper
• Somatic mutations lead to an oncogenic deletion of met in lung cancer.

  2006cited by this paper
• Met/Hepatocyte Growth Factor Receptor Ubiquitination Suppresses Transformation and Is Required for Hrs Phosphorylation

  2005cited by this paper
• Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

  2005cited by this paper
• Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture

  2004cited by this paper
• c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

  2003cited by this paper
• Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.

  2001cited by this paper
• Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET

  1999cited by this paper
• Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site.

  1994cited by this paper

• Clinically actionable stratification of uncommon MET fusions: a precision oncology framework

  2026cites this paper
• Urothelial Carcinoma With a Novel MET Exon 14 Skipping Alteration

  2026cites this paper
• The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology

  2026cites this paper
• Recent Advances in Pyridine and Pyrimidine Based Scaffolds as c-Met Kinase Inhibitors for Cancer Therapy: Biological Insights, Docking and SAR

  2026cites this paper
• Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances

  2026cites this paper
• Successful treatment with tepotinib followed by pembrolizumab in pulmonary pleomorphic carcinoma harbouring a MET exon 14 skipping mutation: A case report.

  2026cites this paper
• LINE-1 retrotransposition is a recurrent cause of MET exon 14 skipping in cancer

  2026cites this paper
• The Mutation Patterns of MET Gene in Lung Cancer and Brain Tumors: Clinical and Therapeutic Implications

  2026cites this paper
• Analysis of zebrafish homologs within the human genome provides valuable insights into exploring pan-cancer alternative splicing events as prognostic markers and therapeutic targets

  2025cites this paper
• Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy.

  2025cites this paper
• Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer

  2025cites this paper
• Autoregulation of the MET receptor tyrosine kinase by its intracellular juxtamembrane domain

  2025cites this paper
• Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression

  2025cites this paper
• Immune and Genomic Heterogeneity of MET-Altered Non-Small Cell Lung Cancer.

  2025cites this paper
• Evolving roles of MET as a therapeutic target in NSCLC and beyond

  2025influential citation
• MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype

  2025cites this paper
• MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

  2025cites this paper
• Alternative Splicing in Lung Adenocarcinoma: From Bench to Bedside

  2025cites this paper
• Dual Drug Nanoformulations for Non-Small Cell Lung Cancer Therapeutics: A Systematic Review

  2025cites this paper
• Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies

  2025cites this paper
• Molecular characterization of EBV-associated primary pulmonary lymphoepithelial carcinoma by multiomics analysis

  2025cites this paper
• Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS

  2025cites this paper
• Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

  2025cites this paper
• Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.

  2025cites this paper
• Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy

  2025cites this paper
• Fusion transcriptome landscape in glioblastoma: Incidence and therapeutic implications

  2025cites this paper
• Comprehensive map of the regulatory network triggered by MET exon 14 skipping reveals important involvement of the RAS-ERK signaling pathway

  2025cites this paper
• MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies

  2025influential citation
• A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025

  2025cites this paper
• Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series.

  2025cites this paper
• The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer

  2025cites this paper
• MET Activation in Lung Cancer and Response to Targeted Therapies

  2025cites this paper
• From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping

  2025cites this paper
• Improvement of Diagnostics in NSCLC Patients with MET Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations

  2025influential citation
• Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancer

  2025influential citation
• Clinical case report on the efficacy and safety of savolitinib in elderly patients with non-small cell lung cancer harboring METex14 skipping mutations

  2025cites this paper
• Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

  2025cites this paper
• Loss of DDX24 inhibits lung cancer progression by stimulating IKBKG splicing-mediated autophagy

  2025cites this paper
• Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer

  2025cites this paper
• Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning

  2025cites this paper
• Patients With Advanced Non-small Cell Lung Cancer Harboring MET Alterations: A Descriptive Cohort Study.

  2025cites this paper
• hnRNPU-mediated pathogenic alternative splicing drives gastric cancer progression

  2025cites this paper
• MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

  2025cites this paper
• Molecular mechanism of type ib MET inhibitors and their potential for CNS tumors

  2025cites this paper
• Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world

  2025cites this paper
• Identification of ALK, ROS1, RET, MET Mutation in EGFR Wild-Type Non-Small Cell Lung Cancer Patients and Their Associations with Clinicopathological Factors

  2025cites this paper
• Molecular Profiling: Genomic-Guided Therapy for Lung Adenocarcinoma

  2025cites this paper
• RNA splicing: Novel star in pulmonary diseases with a treatment perspective

  2025cites this paper
• Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications

  2025cites this paper
• Epigenetic Regulation and Therapeutic Targeting of Alternative Splicing Dysregulation in Cancer

  2025cites this paper
• Neoadjuvant tepotinib in stage IIB N0 non-small cell lung carcinoma with MET exon 14 skipping mutation: a case report and review of the literature

  2025cites this paper
• MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience

  2025cites this paper
• Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy

  2025cites this paper
• Challenges in Amplicon-Based DNA NGS Identification of MET Exon 14 Skipping Events in Non-Small Cell Lung Cancers

  2025cites this paper
• The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma

  2025cites this paper
• First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

  2025cites this paper
• The genomic landscape of lung cancer in never-smokers from the Women’s Health Initiative

  2024cites this paper
• Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance

  2024cites this paper
• Precision oncology: current and future platforms for treatment selection.

  2024cites this paper
• Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.

  2024cites this paper
• Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features

  2024cites this paper
• Understanding variants of unknown significance and classification of genomic alterations

  2024cites this paper
• The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

  2024cites this paper
• A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases

  2024cites this paper
• Drug-induced liver injury associated with savolitinib: a novel case report and causality assessment

  2024cites this paper
• Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning

  2024cites this paper
• Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?

  2024cites this paper
• Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.

  2024cites this paper
• Prevention of Brain Metastases: A New Frontier

  2024cites this paper
• Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study

  2024cites this paper
• The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy

  2024influential citation
• The HGF/Met Receptor Mediates Cytotoxic Effect of Bacterial Cyclodipeptides in Human Cervical Cancer Cells.

  2024cites this paper
• One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas.

  2024cites this paper
• Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology

  2024cites this paper
• Oncogenic alterations in advanced NSCLC: a molecular super-highway

  2024cites this paper
• Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.

  2024cites this paper
• Lung cancer in patients who have never smoked — an emerging disease

  2024cites this paper
• MET alterations in advanced non-small cell lung cancer.

  2024cites this paper
• Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification

  2024cites this paper
• Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance

  2024cites this paper
• MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

  2024cites this paper
• Targeting MET in NSCLC: An Ever-Expanding Territory

  2024cites this paper
• c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.

  2024cites this paper
• Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions

  2024cites this paper
• Advances in Non-Small Cell Lung Cancer (NSCLC) Treatment—A Paradigm Shift in Oncology

  2024cites this paper
• Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

  2024cites this paper
• The rapidly changing field of predictive biomarkers of non-small cell lung cancer

  2024cites this paper
• Encapsulating Epigallocatechin-3-Gallate (EGCG) in Chitosan Nanoparticles Influenced Multiple Genes Controlling Oncostatic Signaling Pathways in HepG2 Cells

  2024cites this paper
• Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

  2024cites this paper
• Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600EMT colon cancer patient with acquired C-MET amplification and TPM4-ALK fusion: a case report

  2024cites this paper
• Microdissection of Distinct Morphological Regions Within Uveal Melanomas Identifies Novel Drug Targets

  2024cites this paper
• Recording and classifying MET receptor mutations in cancers

  2024influential citation
• Non-Small Cell Lung Cancer, Version 4.2024.

  2024cites this paper
• Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study

  2024cites this paper
• Challenges in Therapeutically Targeting the RNA‐Recognition Motif

  2024cites this paper
• MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients

  2024cites this paper
• Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

  2024cites this paper
• How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer.

  2024cites this paper
• Adenocarcinoma of the rete testis: clinicopathological study of 18 cases with emphasis on MET amplification and a review of the literature

  2024cites this paper
• Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

  2024cites this paper